Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 8:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: IBS Group Clear all
Completed Phase 3 Interventional Results available

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02107196
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Ibodutant 10 mg, Placebo
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
65
States / cities
Huntsville, Alabama • Sherwood, Arizona • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Sep 20, 2026, 8:01 AM EDT
Terminated Phase 3 Interventional Results available

52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02120027
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Ibodutant 10 mg, Placebo
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
73
States / cities
Chandler, Arizona • Glendale, Arizona • Mesa, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 20, 2026, 8:01 AM EDT
Not listed Phase 2Phase 3 Interventional

Probiotic (Visbiome) for Gulf War Illness

NCT03078530
View directory record Official record
Conditions
Gulf War Illness
Interventions
Placebo, Visbiome, VSL#3
Drug
Lead sponsor
Ashok Tuteja
Federal
Eligibility
35 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 20, 2026, 8:01 AM EDT
Completed Not applicable Interventional

FODMAP Reintroduction in Irritable Bowel Syndrome

NCT03245645
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome With Mixed Bowel Habits
Interventions
Dietary Intervention
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Sep 20, 2026, 8:01 AM EDT
Completed Not applicable Interventional Results available

Evaluating the Efficacy of the Mediterranean Diet to the Low- Fermentable, Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (FODMAP) Diet in Treating Irritable Bowel Syndrome(IBS)

NCT05807919
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Diet low in all FODMAP groups, Diet - Mediterranean
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 20, 2026, 8:01 AM EDT
Not listed Phase 2 Interventional

Acupuncture/Moxibustion for Irritable Bowel Syndrome (IBS)

NCT00945074
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Standard Acupuncture/Moxibustion (fixed protocol), Individualized Acupuncture/Moxibustion, Sham/Placebo Acupuncture/Moxibustion
Other
Lead sponsor
New York University
Other
Eligibility
18 Years to 70 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Sep 20, 2026, 8:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design

NCT04005456
View directory record Official record
Conditions
Health, Subjective, Gastrointestinal Dysfunction, Cardiovascular Risk Factor, Autoimmune Diseases, Dental Diseases, Hormone Disturbance, Neurocognitive Dysfunction
Interventions
Supplements and/or medical foods, Behavioral change support program, Food plan
Dietary Supplement · Behavioral · Other
Lead sponsor
Metagenics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Gig Harbor, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Sep 20, 2026, 8:01 AM EDT
Completed Not applicable Interventional

Endpoint Determination Study Protocol

NCT03459482
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Food Elimination Diet
Other
Lead sponsor
Biomerica
Industry
Eligibility
21 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Wauconda, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2024 · Synced Sep 20, 2026, 8:01 AM EDT
Completed Not applicable Interventional

Effects of Relaxation Response Mind-body Intervention in Patients With IBS and IBD

NCT02136745
View directory record Official record
Conditions
Irritable Bowel Syndrome, Inflammatory Bowel Disease
Interventions
Relaxation Response Mind-Body Intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 20, 2026, 8:01 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use

NCT02959983
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
76
States / cities
Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 20, 2026, 8:01 AM EDT
Recruiting Phase 2 Interventional

Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

NCT03339128
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
26
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Corona, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 20, 2026, 8:01 AM EDT
Completed Phase 2 Interventional Results available

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT02559206
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide, Matching Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
71
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 20, 2026, 8:01 AM EDT
Completed Phase 3 Interventional

Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

NCT00067561
View directory record Official record
Conditions
Irritable Colon, Irritable Bowel Syndrome (IBS)
Interventions
Alosetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
177
States / cities
Birmingham, Alabama • Calera, Alabama • Tuscaloosa, Alabama + 149 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 20, 2026, 8:01 AM EDT
Suspended Phase 2 Interventional

A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)

NCT01076699
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
0.075 mg RVX-100, 0.125 mg RVX-100, 0.250 mg RVX-100, placebo
Drug
Lead sponsor
Revogenex, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chevy Chase, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2010 · Synced Sep 20, 2026, 8:01 AM EDT
Completed Phase 4 Interventional

Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)

NCT00610909
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Paroxetine CR, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Sep 20, 2026, 8:01 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS

NCT00258193
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
MD-1100 Acetate
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2006 · Synced Sep 20, 2026, 8:01 AM EDT
Completed Not applicable Interventional Results available

Acceptability and Efficacy of the Zemedy App for Irritable Bowel Syndrome

NCT04170686
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Zemedy App for Irritable Bowel Syndrome
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Sep 20, 2026, 8:01 AM EDT
Completed Not applicable Interventional

Well-being in IBS: Strengths and Happiness (WISH)

NCT05289089
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Positive Psychology Intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 20, 2026, 8:01 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

NCT00394173
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea (IBS-D)
Interventions
DNK333, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
180 participants
Timeline
2006 – 2007
U.S. locations
37
States / cities
Tucson, Arizona • North Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 20, 2026, 8:01 AM EDT
Not listed Not applicable Interventional

Patient Attributes for Optimal Treatment Outcome in Irritable Bowel Syndrome.

NCT01297556
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Cognitive Behavior Therapy(CBT)
Behavioral
Lead sponsor
Michigan Gastroenterology Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 15, 2011 · Synced Sep 20, 2026, 8:01 AM EDT
Completed Not applicable Interventional

Mindfulness vs. Support Groups for Irritable Bowel Syndrome

NCT00680693
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Mindfulness training, Psycho-educational support group for women with IBS
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Sep 20, 2026, 8:01 AM EDT
Completed Not applicable Interventional Results available

Gulf War Digestive Health Study

NCT00680836
View directory record Official record
Conditions
Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Interventions
Placebo, Rifaximin
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
35 Years to 72 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Sep 20, 2026, 8:01 AM EDT
Completed Not applicable Interventional

Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth

NCT02251483
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Interventions
Serum-derived bovine immunoglobulin protein isolate (SBI), Placebo
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Sep 20, 2026, 8:01 AM EDT
Completed Not applicable Interventional

SMART Program in Irritable Bowel Syndrome (IBS)

NCT03454386
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Stress Management and Resilience Training Program, Self-Management Stress Reduction Program
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Sep 20, 2026, 8:01 AM EDT